RxDoctor Payments Data

Jonathan Lown, MD

Internal Medicine · Commack, NYNPI 1265538458

Payments from drug & device makers

$337,819in general payments, 2019–2025

Across 1,946 payments — averaging $173.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Esperion Therapeutics, Inc.$172K
  • Harmony Biosciences LLC$68K
  • Jazz Pharmaceuticals Inc.$42K
  • Idorsia Pharmaceuticals US Inc$26K
  • Amgen$5K
  • AstraZeneca$2K
  • plus $24K from 54 others

What the payments were for

  • Consulting fees$15,7515%
  • Speaking & faculty fees$236,13070%
  • Travel & lodging$43,58413%
  • Food & beverage$41,67312%
  • Education$6260%
  • Entertainment$550%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Esperion Therapeutics, Inc.203$171,655
Harmony Biosciences LLC244$67,832
Jazz Pharmaceuticals Inc.123$41,575
Idorsia Pharmaceuticals US Inc57$25,587
Amgen136$4,942
AstraZeneca77$1,852
Inspire Medical Systems, Inc.15$1,602
AbbVie(2 entities)95$1,561
Optinose US, Inc.25$1,553
Biohaven Pharmaceuticals, Inc.7$1,470
Sumitomo Pharma America, Inc.42$1,297
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC89$1,242
Lilly USA, LLC66$1,030
Novo Nordisk44$916
Axsome Therapeutics, Inc.49$902
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)49$860
Merck49$832
Pacira Therapeutics, Inc.16$818
Novartis52$772
Bayer48$761
Pfizer52$730
Amarin Pharma, Inc.30$577
Regeneron Healthcare Solutions, Inc.32$565
Corcept Therapeutics26$461
Azurity Pharmaceuticals, Inc.43$425
Astellas Pharma US Inc9$346
Eisai Inc.25$339
Johnson & Johnson18$326
Takeda Pharmaceuticals U.S.A., Inc.21$303
GSK13$283
Medtronic(2 entities)3$259
Biohaven Pharmaceutical Holding Company Ltd.13$247
Boehringer Ingelheim5$214
Electromed, Inc.14$209
Philips North America LLC11$201
IBSA Pharma Inc.5$179
Arbor Pharmaceuticals, Inc.12$170
Daiichi Sankyo Inc.8$146
Ionis Pharmaceuticals, Inc.3$143
Abbott7$142
Radius Health, Inc.6$142
Alfasigma USA, Inc.7$130
Avadel CNS Pharmaceuticals, LLC6$128
Genentech USA, Inc.6$128
ZOLL Respicardia, Inc.3$113
Lundbeck LLC6$110
Regeneron1$103
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)1$99
Ardelyx, Inc.4$94
Xeris Pharmaceuticals, Inc.4$82
Bioxcel Therapeutics, Inc.3$79
Kowa Pharmaceuticals America, Inc.5$78
Teva Pharmaceuticals USA, Inc.5$69
Almatica Pharma LLC3$67
Resmed Corp3$66
Respire Medical Holdings LLC1$65
Scilex Pharmaceuticals Inc.3$63
Itamar Medical Inc1$55
Bausch Health US, LLC3$53
Neuronetics, Inc.2$50

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$337,819 in reported general payments places this provider in the 95th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$509,815
Medicare patients
477
Services billed
15,657

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide516$565,570
Repatha SureclickEvolocumab278$248,919
NexlizetBempedoic Acid/Ezetimibe174$160,972
OzempicSemaglutide133$143,395
FarxigaDapagliflozin Propanediol148$133,181
JardianceEmpagliflozin106$121,838
EliquisApixaban77$104,348
EntrestoSacubitril/Valsartan72$90,659
KerendiaFinerenone67$81,303
VascepaIcosapent Ethyl70$60,745
XareltoRivaroxaban36$56,807
TrulicityDulaglutide39$54,168
Xigduo XrDapaglifloz Propaned/Metformin24$39,822
Synjardy XrEmpagliflozin/Metformin Hcl31$34,000
MyrbetriqMirabegron29$30,942

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$1,030$619,738555 claims
Esperion Therapeutics, Inc.Nexlizet, Nexletol$171,655$176,281192 claims
Boehringer IngelheimJardiance, Synjardy Xr$214$155,838137 claims
AstraZenecaFarxiga, Lokelma$1,852$150,444169 claims
Novo NordiskOzempic$916$143,395133 claims
PfizerEliquis$730$104,34877 claims
NovartisEntresto$772$90,65972 claims
BayerKerendia$761$81,30367 claims
GSKAnoro Ellipta, Arexvy, Shingrix, Trelegy Ellipta, Breo Ellipta$283$67,590181 claims
Johnson & JohnsonXarelto$326$56,80736 claims
Astellas Pharma US IncMyrbetriq$346$30,94229 claims
MerckBelsomra, Verquvo$832$30,88758 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Commack

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →